Literature DB >> 28496821

Emergency Physician Patterns Related to Anticoagulation of Patients with Recent-Onset Atrial Fibrillation and Flutter.

Paraish Misra1, Eddy Lang1, Catherine M Clement2, Robert J Brison3, Brian H Rowe4, Bjug Borgundvaag5, Trevor Langhan1, Kirk Magee6, Rob Stenstrom7, Jeffrey J Perry8, David Birnie9, George A Wells10, X Xue10, G Innes1, Ian G Stiell8.   

Abstract

Guidelines strongly recommend long-term anticoagulation with warfarin for patients with newly recognized AF who have high embolic risk by virtue of a CHADS2 (Congestive Heart Failure, Hypertension, Age >65, Diabetes, History of Stroke) score ≥ 2. The goal of this study was to determine patterns of emergency department-initiated anticoagulation among eligible patients discharged from Canadian centers with an episode of recent-onset atrial fibrillation and flutter (RAFF) and determine if decision-making is driven by the CHADS2 score or other factors. This was accomplished by examining health records using uniform case identification and data abstraction as well as centralized quality control; it was conducted in 8 Canadian university emergency departments over a 12-month period. Eligible patients for this analysis demonstrated RAFF requiring emergency management, were not already taking warfarin and were not admitted to hospital. Univariate analyses were conducted using T-test or Chi-square to select factors associated with anticoagulation initiation at a significance level of p < 0.15 and multiple logistic regression was employed to evaluate independent predictors after adjustment for confounders. Among 633 eligible patients, only 21 out of 120 patients (18%) with a CHADS2 score ≥ 2 received anticoagulation and among 70 patients who were given anticoagulation only 21 (30%) had a CHADS2 score ≥ 2. Independent predictors of anticoagulation included age by 10-year strata: (OR = 1.7; 95% CI 1.3 - 2.1), heparin use in the anticoagulation (OR = 9.6; 95% CI 4.9 - 18.9), a new prescription for metoprolol (OR = 9.6; 95% CI 4.9 - 18.9) and being referred to cardiology for follow-up (OR = 5.6; 95% CI 2.6 - 12.0). CHADS2 ≥ 2 doubled the likelihood of being prescribed anticoagulation (OR= 2.0; 95% CI 1.5 - 3.5) but was not an independent predictor. It was thus determined that patients discharged from the emergency department in this study were not prescribed anticoagulation in keeping with current recommendations. This practice gap merits further investigation and may benefit from educational efforts or enhanced support for anticoagulation use from the emergency department.

Entities:  

Year:  2013        PMID: 28496821      PMCID: PMC5153167          DOI: 10.4022/jafib.645

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  13 in total

1.  Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores.

Authors:  Burak Pamukcu; Gregory Y H Lip; Deirdre A Lane
Journal:  Age Ageing       Date:  2010-05-26       Impact factor: 10.668

2.  Risk of stroke in patients with atrial flutter.

Authors:  L A Biblo; Z Yuan; K J Quan; J A Mackall; A A Rimm
Journal:  Am J Cardiol       Date:  2001-02-01       Impact factor: 2.778

3.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

4.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2006-05-26       Impact factor: 29.983

Review 5.  Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

Authors:  Fazeel M Siddiqui; Adnan I Qureshi
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

6.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

7.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?

Authors:  Peter J Zimetbaum; Amit Thosani; Hsing-Ting Yu; Yan Xiong; Jay Lin; Prajesh Kothawala; Matthew Emons
Journal:  Am J Med       Date:  2010-05       Impact factor: 4.965

Review 8.  Prevention of stroke in patients with high-risk atrial fibrillation.

Authors:  Richard A Bernstein; Rod Passman
Journal:  Curr Neurol Neurosci Rep       Date:  2010-01       Impact factor: 5.081

9.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

Authors:  John A Cairns; Stuart Connolly; Sean McMurtry; Michael Stephenson; Mario Talajic
Journal:  Can J Cardiol       Date:  2011 Jan-Feb       Impact factor: 5.223

10.  Use of the CHADS2 risk score to guide antithrombotic treatment in patients with atrial fibrillation--room for improvement.

Authors:  David R Altmann; Michael Kühne; Christian Sticherling; Stefan Osswald; Beat A Schaer
Journal:  Swiss Med Wkly       Date:  2010-02-06       Impact factor: 2.193

View more
  2 in total

1.  Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation.

Authors:  Clare L Atzema; Cynthia A Jackevicius; Alice Chong; Paul Dorian; Noah M Ivers; Ratika Parkash; Peter C Austin
Journal:  CMAJ       Date:  2019-12-09       Impact factor: 8.262

2.  Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department.

Authors:  David R Vinson; E Margaret Warton; Dustin G Mark; Dustin W Ballard; Mary E Reed; Uli K Chettipally; Nimmie Singh; Sean Z Bouvet; Bory Kea; Patricia C Ramos; David S Glaser; Alan S Go
Journal:  West J Emerg Med       Date:  2018-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.